MediLumine 特约代理

发表于由

世界*实验材料供应商 MediLumine 上海金畔生物为其中国代理， MediLumine 在一直是行业的*,一直为广大科研客户提供zui为的产品和服务,上海金畔生物一直秉承为中国科研客户带来的产品，的服务， MediLumine 就是为了给广大科研客户带来更加完善的产品和服务,您的满意将是我们zui大的收获

 MediLumine 中国代理, MediLumine 上海代理， MediLumine 北京代理，MediLumine 广东代理， MediLumine 江苏代理MediLumine 湖北代理,MediLumine 天津,MediLumine 黑龙江代理,MediLumine 内蒙古代理,MediLumine 吉林代理,MediLumine 福建代理, MediLumine 江苏代理, MediLumine 浙江代理, MediLumine 四川代理,

MediLumine（发音为ˌ mɛdilu 分钟）是临床前小动物造影剂用于显微CT成像的*的供应商。我们的Fenestra®和Mvivo™造影剂用于广泛的应用，如肝脏疾病（如糖尿病，脂肪肝疾病，肝转移）的检测，分期和监测以及血管生成或心血管疾病研究的血管成像。

我们使用专有的脂质，聚合物，多糖，水凝胶和纳米颗粒技术的CRO配方开发服务使我们成为成像，药理学和药物传递研究的合作伙伴。

Fenestra® Imaging Agents

Fenestra® is a licensed technology that solves several key problems associated with micro-CT imaging. This biochemically activated emulsion is comprised of iodinated lipids that provide contrast enhancement and a novel oil-in-water lipid emulsion that selectively localizes the lipids for small animal imaging. The unique Fenestra® formulation is biodegradable and compley eliminated by hepatocyte metabolism.

  • Fenestra VC
  • Fenestra LC

Mvivo™ Imaging Agents

Mvivo™ is our nanoparticle contrast agent line of products for in-vivo imaging. These contrast agents are are ideal for applications such as targeted imaging, vascular and tumor imaging, techniques that require high resolution contrast agents to match the higher resolution preclinical imaging modalities:

  • Mvivo Au
  • Mvivo AuNHS
  • Mvivo BIS
  • Mvivo USPIO

Bradykinin Receptor Modulators

Based on a proprietary sequence of natural and unnatural amino acids, the biostable B1R agonist for blood brain tumor barrier (BBTB) permeabilization, B2R for general blood brain barrier permeabilization and B1R/B2R agonist for optimum BBTB/BBB permeabilization are available exclusively through MediLumine.  MediLumine offers three different peptide agonists which are ideal for co-injection with other contrast agents and possible therapeutic compounds to cross the blood brain barrier.

These agonists can also be used for other applications since recent publications have shown that they are expressed in other disease states.

  • Bradykinin B1 Receptor Agonist
  • Bradykinin B2 Receptor Agonist
  • Bradykinin B1/B2 Receptor Agonist 

Systems & Accessories

MediLumine™ offers accessories and high quality hardware solutions for challenging aspects of preclinical in vivo research such as control/maintenance of animal body temperature during experimental surgery, high quality anesthesia and performing successful tail vein injection:

  • Small Animal Gas Anesthesia Systems
  • Vaporizer for Small Animal Anesthesia
  • Anesthetic Diverter Manifold Systems
  • Multiplex Delivery Systems
  • Vaporizer Fill Devices
  • Rodent Face Mask Systems
  • Induction Chambers
  • CO2 Induction System
  • Mouse & Rat Restrainers for Tail Vein Injections
  • Mouse Induction Chamber for Tail Vein Injections

micro-CT Contrast Agent with Multiple Applications

Product: Fenestra® VC
Composition: 1,3-bis-[7-(3-amino-2,4,6-triiodophenyl)-heptanoyl]-2-oleoyl glycerol (DHOG) in a 20% (w/v) total triglyceride oil-in-water pegylated emulsion with 10% DHOG (nominal 50 mg I/mL)
Description: Fenestra VC contrast agent is used for preclinical angiography, liver and spleen imaging of small animals.   It is a specialized version of Fenestra LC in which the surface of the lipid emulsion particles is modified with DSPE-PEG so as to alter the recognition of the particle by the receptors on hepatocytes that are responsible for its uptake into the liver.  With Fenestra VC, the delayed uptake by liver cells produces an agent with superior blood pool imaging properties that last for several hours after injection. Like its liver-selective counterpart, Fenestra VC is eventually metabolized and eliminated through the hepatobiliary system.
Application: Quantitation of metastatic tumour burdens in liver, angiography, assessing anti-angiogenesis, 4D Cardiac imaging, soft tissue contrast for multimodal imaging.
Disciplines: Oncology, cardiovascular, drug delivery, imaging research

micro-CT Contrast Agent with Multiple Applications

Product: Fenestra® LC
Composition: 1,3-bis-[7-(3-amino-2,4,6-triiodophenyl)-heptanoyl]-2-oleoyl glycerol (DHOG) in a 20% (w/v) total triglyceride oil-in-water emulsion with 10% DHOG (nominal 50 mg I/mL)
Description: MediLumine’s Fenestra LC provides visualization of the hepatobiliary system by exploiting the endogenous lipid metabolism pathways present in the body. Fenestra LC mimics chylomicron remnant particles and thereby localizes the contrast-producing lipids it contains into the hepatic parenchyma.  Because the uptake and clearance profiles of the lipid molecules are determined by the metabolic status of extracellular and intracellular liver lipases, Fenestra LC provides the ability to assess both hepatobiliary anatomy as well as liver function by CT imaging.
Application: Detection, staging, and monitoring of parenchymal liver diseases, Quantitation of metastatic tumour burdens in soft tissues, soft tissue contrast for multimodal imaging.
Disciplines: Diabetes, Fatty Liver Disease, Oncology, Drug Discovery & Imaging Research